Skip to main content
Top
Literature
2.
go back to reference Mouchli M, Reddy S, Gerrard M et al (2021) Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Rev Artic Ann Hepatol 22:100249CrossRef Mouchli M, Reddy S, Gerrard M et al (2021) Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Rev Artic Ann Hepatol 22:100249CrossRef
3.
go back to reference Bedel C, Korkut M, Armağan HH (2021) NLR, d-NLR and PLR can be affected by many factors. Int Immunopharmacol 90:107154CrossRefPubMed Bedel C, Korkut M, Armağan HH (2021) NLR, d-NLR and PLR can be affected by many factors. Int Immunopharmacol 90:107154CrossRefPubMed
5.
go back to reference Sharon N, Talnir R, Lavid O et al (2011) Transient lymphopenia and neutropenia: pediatric influenza A/H1N1 infection in a primary hospital in Israel. Isr Med Assoc J IMAJ 13(7):408–412PubMed Sharon N, Talnir R, Lavid O et al (2011) Transient lymphopenia and neutropenia: pediatric influenza A/H1N1 infection in a primary hospital in Israel. Isr Med Assoc J IMAJ 13(7):408–412PubMed
Metadata
Title
Neutrophil-to-lymphocyte ratio is an independent risk factor for proteinuria non-remission in idiopathic membranous nephropathy
Authors
Ning Zhuo
Gang Wang
Gang Wu
Publication date
03-11-2023
Publisher
Springer Netherlands
Keyword
COVID-19
Published in
International Urology and Nephrology / Issue 5/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03871-z

Other articles of this Issue 5/2024

International Urology and Nephrology 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine